Public Employees Retirement System of Ohio Sells 350 Shares of Ascendis Pharma A/S $ASND

Public Employees Retirement System of Ohio trimmed its position in Ascendis Pharma A/S (NASDAQ:ASND) by 4.7% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 7,026 shares of the biotechnology company’s stock after selling 350 shares during the period. Public Employees Retirement System of Ohio’s holdings in Ascendis Pharma A/S were worth $1,213,000 at the end of the most recent reporting period.

Other large investors have also recently bought and sold shares of the company. Compagnie Lombard Odier SCmA bought a new position in Ascendis Pharma A/S in the 2nd quarter valued at $39,000. Brooklyn Investment Group boosted its holdings in Ascendis Pharma A/S by 332.9% in the 1st quarter. Brooklyn Investment Group now owns 355 shares of the biotechnology company’s stock valued at $55,000 after purchasing an additional 273 shares during the period. Dearborn Partners LLC bought a new stake in shares of Ascendis Pharma A/S during the 1st quarter worth $203,000. New Wave Wealth Advisors LLC bought a new stake in shares of Ascendis Pharma A/S during the 1st quarter worth $222,000. Finally, Pursue Wealth Partners LLC bought a new stake in shares of Ascendis Pharma A/S during the 1st quarter worth $226,000.

Analyst Upgrades and Downgrades

A number of analysts have recently issued reports on the stock. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Ascendis Pharma A/S in a report on Saturday, September 27th. Oppenheimer reaffirmed an “outperform” rating and set a $224.00 price objective (up from $215.00) on shares of Ascendis Pharma A/S in a report on Friday, June 13th. UBS Group reaffirmed a “buy” rating and set a $307.00 price objective (up from $306.00) on shares of Ascendis Pharma A/S in a report on Friday, August 8th. Morgan Stanley assumed coverage on shares of Ascendis Pharma A/S in a report on Thursday, July 3rd. They set an “overweight” rating and a $250.00 price objective for the company. Finally, Cantor Fitzgerald lifted their price objective on shares of Ascendis Pharma A/S from $200.00 to $203.00 and gave the stock an “overweight” rating in a report on Friday, August 8th. Fifteen investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. According to MarketBeat, Ascendis Pharma A/S has an average rating of “Moderate Buy” and a consensus price target of $244.36.

Ascendis Pharma A/S Price Performance

Shares of NASDAQ ASND opened at $204.05 on Friday. Ascendis Pharma A/S has a 1 year low of $118.03 and a 1 year high of $208.16. The company’s 50-day moving average is $192.77 and its 200 day moving average is $174.11. The stock has a market capitalization of $12.57 billion, a P/E ratio of -39.54 and a beta of 0.41.

Ascendis Pharma A/S (NASDAQ:ASND) last announced its quarterly earnings results on Thursday, August 7th. The biotechnology company reported ($0.93) earnings per share (EPS) for the quarter, beating the consensus estimate of ($1.42) by $0.49. The company had revenue of $216.28 million for the quarter, compared to analysts’ expectations of $163.17 million. Research analysts anticipate that Ascendis Pharma A/S will post -4.34 earnings per share for the current year.

Ascendis Pharma A/S Company Profile

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.